机构：[1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.[2]Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Southwest Medical University, Luzhou 646000, China.[3]South Sichuan Institute of Translational Medicine, Luzhou 646000, China.[4]Department of Pharmacy, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou 646000, China.[5]Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, China.[6]Department of Oncology and Hematology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou 646000, China.
Over the past decade, immunotherapy, especially cell-based immunotherapy, has provided new strategies for cancer therapy. Recent clinical studies demonstrated that adopting cell transfer of tumor-infiltrating lymphocytes (TILs) for advanced solid tumors showed good efficacy. TIL therapy is a type of cell-based immunotherapy using the patient's own immune cells from the microenvironment of the solid tumor to kill tumor cells. In this review, we provide a comprehensive summary of the current strategies and challenges in TIL isolation and generation. Moreover, the current clinical experience of TIL therapy is summarized and discussed, with an emphasis on lymphodepletion regimen, the use of interleukin-2, and related toxicity. Furthermore, we highlight the clinical trials where TIL therapy is used independently and in combination with other types of therapy for solid cancers. Finally, the limitations, future potential, and directions of TIL therapy for solid tumor treatment are also discussed.
基金：
the National Natural Science Foundation of China, grant
number 81972643, and by the Science and Technology Strategic Cooperation Programs of Luzhou
Municipal People’s Government and Southwest Medical University, grant number 2019LZXNYDJ45.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类|2 区医学
小类|2 区肿瘤学
最新[2023]版：
大类|2 区医学
小类|3 区肿瘤学
第一作者：
第一作者机构：[1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.[2]Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Southwest Medical University, Luzhou 646000, China.[3]South Sichuan Institute of Translational Medicine, Luzhou 646000, China.
共同第一作者：
通讯作者：
通讯机构：[1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.[2]Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Southwest Medical University, Luzhou 646000, China.[3]South Sichuan Institute of Translational Medicine, Luzhou 646000, China.[5]Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, China.
推荐引用方式(GB/T 7714)：
Zhao Yueshui,Deng Jian,Rao Shuangfeng,et al.Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges[J].Cancers.2022,14(17):doi:10.3390/cancers14174160.
APA：
Zhao Yueshui,Deng Jian,Rao Shuangfeng,Guo Sipeng,Shen Jing...&Li Jing.(2022).Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges.Cancers,14,(17)
MLA：
Zhao Yueshui,et al."Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges".Cancers 14..17(2022)
医学